Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Kathleen Moore is the Virginia Kerley Cade Endowed Chair in Cancer Development and Professor of Gynecologic Oncology in the Department of Obstetrics and Gynecology at the University of Oklahoma Health Sciences Center. She currently serves as the Associate Director of Clinical Research and the Director of the Oklahoma TSET Phase I Program at the Stephenson Cancer Center. She also serves as the Associate Program Director of the Gyn Oncology Fellowship Program in the Section of Gyn Oncology of the Department of OB/GYN. She completed her gyn oncology fellowship at the University of Oklahoma Health Sciences Center in 2007 and was recruited to join the faculty. Her primary areas of interest are in new drug development and Phase I clinical trials.
Alkermes (Individual(s) Involved: Self): Advisory Board; Aravive (Individual(s) Involved: Self): Advisory Board; AstraZeneca (Individual(s) Involved: Self): Advisory Board; blueprint (Individual(s) Involved: Self): Advisory Board; Eisai Inc (Individual(s) Involved: Self): Advisory Board; Elevar (Individual(s) Involved: Self): Advisory Board; EMD Serono (Individual(s) Involved: Self): Advisory Board; Genentech (Individual(s) Involved: Self): Advisory Board; GOG Foundation (Individual(s) Involved: Self): Advisory Board; GOG Partners (Individual(s) Involved: Self): Advisory Board; GSK/Tesaro (Individual(s) Involved: Self): Advisory Board, Grant/Research Support; Henguri (Individual(s) Involved: Self): Advisory Board; IMab (Individual(s) Involved: Self): Advisory Board; Immunogen (Individual(s) Involved: Self): Advisory Board; INXMED (Individual(s) Involved: Self): Advisory Board; Lilly (Individual(s) Involved: Self): Advisory Board, Grant/Research Support; Merck (Individual(s) Involved: Self): Advisory Board, Grant/Research Support; Mereo Therapeutics (Individual(s) Involved: Self): Advisory Board; Mersana (Individual(s) Involved: Self): Advisory Board; Myriad (Individual(s) Involved: Self): Advisory Board; Novartis (Individual(s) Involved: Self): Advisory Board; OncoNova (Individual(s) Involved: Self): Advisory Board; OncXerna (Individual(s) Involved: Self): Advisory Board; PTC Therapeutics (Individual(s) Involved: Self): Grant/Research Support; Tarveda (Individual(s) Involved: Self): Advisory Board; VBL Therapeutics (Individual(s) Involved: Self): Advisory Board; Verastem (Individual(s) Involved: Self): Advisory Board
Wednesday, April 27, 2022
2:35 PM – 3:25 PM
Thursday, April 28, 2022
11:30 AM – 12:20 PM
Thursday, April 28, 2022
11:50 AM – 12:05 PM
Thursday, April 28, 2022
12:05 PM – 12:20 PM
Friday, April 29, 2022
9:00 AM – 10:00 AM
Friday, April 29, 2022
9:00 AM – 9:05 AM
Friday, April 29, 2022
9:35 AM – 10:00 AM
Friday, April 29, 2022
11:20 AM – 1:25 PM
Friday, April 29, 2022
11:20 AM – 11:25 AM
Friday, April 29, 2022
1:05 PM – 1:25 PM
Friday, April 29, 2022
2:45 PM – 4:30 PM
Friday, April 29, 2022
2:45 PM – 2:50 PM
Friday, April 29, 2022
3:30 PM – 4:00 PM
Friday, April 29, 2022
4:00 PM – 4:30 PM
Thursday, September 22, 2022
9:00 AM – 9:05 AM
Thursday, September 22, 2022
1:55 PM – 3:20 PM
Thursday, September 22, 2022
1:55 PM – 2:00 PM
Thursday, September 22, 2022
3:00 PM – 3:20 PM
Friday, September 23, 2022
8:40 AM – 10:00 AM
Friday, September 23, 2022
8:40 AM – 8:45 AM
Friday, September 23, 2022
9:40 AM – 10:00 AM
Friday, September 23, 2022
11:20 AM – 1:25 PM
Friday, September 23, 2022
11:20 AM – 11:25 AM
Friday, September 23, 2022
12:25 PM – 12:45 PM
Friday, September 23, 2022
1:05 PM – 1:25 PM
Friday, September 23, 2022
1:35 PM – 2:40 PM
Friday, September 23, 2022
1:35 PM – 1:40 PM
Friday, September 23, 2022
2:20 PM – 2:40 PM